EDIL3 and breast carcinoma: These observations were also validated in MDA-MB-231 paclitaxel-resistant breast cancer cells, where higher levels of EDIL3 and SDC2 indicated the involvement of the EMT process in paclitaxel resistance, as reported in ovarian cancer38,39.